Ageronix SA

Analysis

Ageronix SA maintains 1 pending office action in the Biotechnology & Pharmaceuticals technology area. Prosecution is distributed across 1 distinct examiner and 1 distinct art unit. The presence of 1 distinct examiner suggests a streamlined interaction with the USPTO for this portfolio. Because the workload is limited to 1 pending office action, the company can focus its resources on addressing the requirements of this 1 examiner to secure patent rights.

SUDHAKAR KATAKAM is the busiest examiner, responsible for 1 pending office action. This individual is currently the sole gatekeeper for the company's pending intellectual property in the United States. Practitioners should observe that the involvement of 1 distinct art unit simplifies the administrative burden but also means the company's success is tied to the specific examination culture of that unit. The focus on 1 pending office action may indicate a strategic emphasis on a core technology.

The data reflects a lean prosecution profile where every decision made in response to SUDHAKAR KATAKAM carries significant weight. With no other pending actions to manage, the legal team can provide a highly targeted response. This environment is conducive to resolving complex technical rejections that often arise in the Biotechnology & Pharmaceuticals area. Maintaining a single point of contact within 1 distinct art unit allows for a cohesive narrative throughout the prosecution process.